Moderna, Inc., a pioneering biotechnology firm, has been at the forefront of mRNA technology, revolutionizing the way we approach vaccines and therapeutics. As of now, Moderna's stock exhibits strong momentum, capturing the attention of investors and analysts alike. ### Investment Thesis **Strong Momentum:** Moderna's stock has shown impressive performance,...
Here's a small interesting history: In the late 19th century, stock trading took place through an archaic system of handwritten ledger entries and paper shares that had to be physically transported between offices. This cumbersome process led to frequent errors and delays. In 1887, a group of Wall Street clerks devised a more efficient method by setting up...
🔉Sound on!🔉 Thank you as always for watching my videos. I hope that you learned something very educational! Please feel free to like, share, and comment on this post. Remember only risk what you are willing to lose. Trading is very risky but it can change your life!
If one examines MRNA on the shorter term, the prospective is not so bright. s3.tradingview.com However, when one also examines the longer term, clear accumulation can be seen. s3.tradingview.com
NASDAQ:MRNA Bearish to Bullish Reversal A "Bearish to Bullish Reversal" in technical analysis for NASDAQ:MRNA suggests a shift in the stock's price movement pattern from a downward trend (bearish) to an upward trend (bullish). This reversal typically occurs after a period of decline, indicating that the stock may be transitioning from a bearish phase to a...
Moderna ( NASDAQ:MRNA ), a biotechnology company at the forefront of mRNA technology, is experiencing a significant surge in its stock price, climbing over 10% to surpass the $114 per share mark. This rally marks Moderna's highest level since January, reflecting a remarkable turnaround from its challenges in 2023. The resurgence of Moderna's stock can be...
NASDAQ:MRNA seems to have found its feet in wave 2. We should be now gearing up for wave 3, price action to get more promising upwards as we cross the diagonal resistance (red line). More on it: - iH&S shoulder also forming on weekly - While the monthly close of Jan wasn't promising, buyers stepped into Feb with a decent closure Disclaimer: This is not...
The biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants. Support and Resistance...
MRNA focuses on vaccine research and development and we are in the flu season an COVID is lurking in the shadows and trying to make a comback. It had an excellent earnings report and forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored VWAP and is at the level of the first upper VWAP while in side the high volume area...
The mRNA stock has exhibited a bullish flag breakout, following the identification of a falling wedge pattern. We anticipate a potential retracement towards the prominent key level near $130, which was established at the top.
Moderna ( NASDAQ:MRNA ), the pioneering vaccine maker, reported a surprise fourth-quarter profit, sending ripples of optimism through the market. Bolstered by unexpected revenue and strategic cost-cutting measures, the company's resilience amid shifting tides in the pharmaceutical landscape has drawn both attention and applause. Unveiling the Numbers: Moderna's (...
Resistance $115.84. Earnings beat could help it break that strong resistance and shoot to $140. Potential Golden Cross could form in the near future.
MRNA seems to finding its feet part of wave-4. If market continues to hold current levels, and goes above..it can hit $120-129 part of wave-5. Disclaimer: This is not financial advice. Please make your own decisions while making an investment.
Looks like the market is giving a break to this stock. I think is going to try the 95 resistance level. Looks oversold and bouncing up from a long term trendline. Also call options is an interesting choice but give it time like a month.
Analysts at the Oppenheimer brokerage company, as reported by Reuters , have upgraded the stock rating of Moderna Inc. to "outperforming the market," and the vaccine maker's CEO reiterated the company's goal of achieving sales growth by 2025. The issuer's shares fell nearly 45% in 2023, marking its worst annual performance due to weak COVID-19 vaccine sales....
NASDAQ:MRNA is taking a breather now but looking to break the 115 mark to move higher.